Myocardial Ischemia Market Segmentation by Route of Administration (Injectable, and Oral); by End-User (Ambulatory Centers, Hospitals & Clinics, and Diagnostic Center); and by Type (Asymptomatic, and Symptomatic)-Global Demand Analysis & Opportunity Outlook 2031
24 Jun 2022
Healthcare & Pharmaceuticals
Impact Analysis on the Growth of Market
Inflation and Looming Recession to Haunt Businesses:
In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022...
The Research Report is Updated with 2021 Base Year, 2022 Estimated year and Forecast till 2031 with Market Insights.
With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2021 as base year, 2022 as estimated year and forecast to 2031. This will have market drivers, recovery rate in the market, insights and competitive analysis.
Global Myocardial Ischemia Market Highlights Over 2022 - 2031
The global myocardial ischemia market is estimated to grow at a ~6% CAGR over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a revenue of approximately USD 1,817.0 million in 2021. The growth of the market can be attributed to the high prevalence of diabetes, cardiovascular, and other diseases worldwide. In addition, there has been a surge in the mortality rate across the globe owing to these chronic diseases, which is also expected to drive the growth of the market in the coming years. According to the World Health Organization (WHO), cardiovascular diseases accounted to 32 percent of all global deaths in the year 2019. Furthermore, an increase in the government and different organizations supporting people suffering from myocardial ischemia is expected to drive the growth of the global myocardial ischemia market.
The global myocardial ischemia market is segmented by type into asymptomatic and symptomatic. Out of these, the asymptomatic segment is anticipated to hold the largest share over the forecast period in the market owing to the rise in the number of silent myocardial ischemia cases that lead to sudden deaths.
Global Myocardial Ischemia Market Regional Synopsis
Regionally, the global myocardial ischemia market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is estimated to witness modest growth over the forecast period on the back of the high prevalence of patients dealing with cardiovascular diseases and diabetes. As per the Centers for Disease Control and Prevention, the 11.3 per cent of the U.S population are suffering from diabetes. Furthermore, advancement in research and development and healthcare infrastructure is further expected to surge the growth of the myocardial ischemia market in the North America region.
Our in-depth analysis of the global myocardial ischemia market includes the following segments:
By Route of Administration
Hospitals & Clinics
Growth Drivers and Challenges Impacting the Growth of the Global Myocardial Ischemia Market
High prevalence of diabetes, cardiovascular, and other diseases
Surge in the mortality rate across the globe due to chronic diseases
High cost for the treatment of myocardial ischemia
Lack of professional medical employees for the treatment of disease
Key Companies Dominating the Global Myocardial Ischemia Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global myocardial ischemia market that are included in our report are Boston Scientific Corporation, PHARMA’S ALMANAC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GSK plc, Bayer AG, RENOVA, Novartis AG, Mylan (Viatris Inc.), Merck KGaA, and others.
Latest Developments in the Global Myocardial Ischemia Market:
25 June 2020: Piramal Pharma announced the acquisition of solid oral dosage drug product facility in Sellersville through agreement with G&W Laboratories Inc.
14 June 2022: Merck KGaA announced its collaboration with Agilent Technologies in order to advance Process Analytical Technologies.
Key Reasons to Buy Our Report
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
The report includes detailed company profiles of the major players dominating the market.
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:
- North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys & Opportunity Outlook
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
FREQUENTLY ASKED QUESTIONS
High prevalence of diabetes, cardiovascular, and other diseases and surge in the mortality rate across the globe followed by the rise in the percentage of people dealing with diseases are the major factors driving the growth of the myocardial ischemia market.
The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2022-2031.
High cost for the treatment of myocardial ischemia and lack of professional medical employees for the treatment of disease are estimated to hamper the market growth.
Which region will provide more business opportunities for growth of myocardial ischemia market in future?
The market in the North America region estimated to witness modest growth over the forecast period and provide more business opportunities for growth of myocardial ischemia market in future.
The major players in the market are Boston Scientific Corporation, PHARMA’S ALMANAC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GSK plc, Bayer AG, RENOVA, Novartis AG, Mylan (Viatris Inc.,), Merck KGaA, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by end-user, type, route of administration, and by region.
The asymptomatic segment is anticipated to hold largest market size in value over the forecast period and display significant growth opportunities.
Please enter your personal details below
- Boston Scientific Corporation
- PHARMA’S ALMANAC
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- GSK plc
- Bayer AG
- Novartis AG
- Mylan (Viatris Inc.)
- Merck KGaA